Business Context and Reporting Period
This Form 8-K filing by CorMedix Inc. covers events occurring on July 18, 2014, and July 21, 2014. The report addresses the company's status regarding NYSE MKT listing compliance and the appointment of new executive officers.
Key Financial Metrics and Liquidity
The filing does not provide current revenue, profit, cash flow, or margin data. However, it references historical financial conditions that triggered listing non-compliance notices:
- Stockholders' Equity: Reported as less than $2,000,000 and less than $4,000,000 as of March 31, 2014.
- Net Losses: The company reported net losses in two of its three most recent fiscal years and in three of its four most recent fiscal years.
- Liquidity/Debt: No specific debt or liquidity figures are provided in this text.
Material Changes and Corporate Actions
Listing Status Update
On July 18, 2014, CorMedix received notice from NYSE MKT LLC that its plan to regain compliance with continued listing standards was accepted. The exchange granted an extension until May 31, 2015, to regain compliance, subject to periodic review.
Executive Appointments
On July 21, 2014, the company appointed:
- Harry O'Grady as Chief Financial Officer (CFO).
- Dr. Antony Pfaffle as Chief Scientific Officer (CSO).
Management Commentary, Compensation, and Risks
Compensation Arrangements
Employment agreements were established with the following terms:
- Base Salaries: $230,000 for Mr. O'Grady and $200,000 for Dr. Pfaffle. Salaries are subject to review in early 2015 to align with market value, with a floor of the initial amounts.
- Incentives: Mr. O'Grady is eligible for a Short Term Incentive Plan (STIP) starting January 1, 2015, with a target of 40% of base salary. Dr. Pfaffle is eligible immediately with a 2015 target of 30% of base salary.
- Equity: Mr. O'Grady received an option to purchase 100,000 shares of common stock, vesting 25% on July 21, 2014, and 25% annually thereafter.
- Termination Provisions: Agreements include acceleration of vesting upon change of control or termination without cause/for good reason. Severance includes 12 months of salary for termination without cause and 180 days of salary for death or disability.
Risks and Contingencies
The primary risk identified is the continued need to meet NYSE MKT listing standards by May 31, 2015, specifically regarding stockholders' equity and profitability history. Failure to comply could result in delisting.
Investor Verification Checklist
- Verify the specific details of the compliance plan accepted by NYSE MKT to ensure the May 31, 2015 deadline is met.
- Review the full employment agreements (Exhibits 10.25 and 10.26) for detailed vesting schedules and termination clauses.
- Monitor upcoming financial reports to assess progress in improving stockholders' equity and reducing net losses.
- Confirm the impact of the new executive leadership on the company's operational strategy and financial outlook.